Vir Biotechnology’s sidelined hepatitis B candidate, designed to serve as a “functional cure,” has failed to achieve the ...

Vir Biotechnology (NASDAQ:VIR) on Friday announced 24-week post-end-of-treatment data from a mid-stage trial for tobevibart ...

The ongoing challenge posed by viral infections to global health has been exemplified by the SARS-CoV-2 pandemic and the continuous threats from pathogens ...